Search Log in
Cancer Drug Resistance
Open Access  ISSN: 2578-532X (Online)   Editor-in-Chief: Godefridus J. Peters
Indexing: ESCI, PMC, Scopus, CAS, CNKI, Dimensions, Lens, Embase®,
Journal Rank: CiteScore 5.5 - Q2 (Pharmacology(medical))   MPT: 114 days
Home Articles Special Issues Volumes Webinars Videos
Home Articles Special Issues Volumes Webinars Videos
It has reached the top

Editorial Board Member

David Gewirtz
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
HomePage
https://pharmtox.vcu.edu/about/our-team/david-a-gewirtz-phd.html
Research Interests
autophagy, senescence, cancer chemotherapy, chemosensitization, radiosensitization, chemtoxicity.
Contributions:

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer

Submit a Manuscript
Manuscript Templates
Aims and Scope
Editorial Board
Submit a Manuscript
Manuscript Templates
Aims and Scope
Editorial Board
Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/
Privacy Cookies Terms of Service Contact Us
Contact Us
partners@oaepublish.com
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
© 2016-2023 OAE Publishing Inc., except certain content provided by third parties